Ipratropium: Difference between revisions
Jump to navigation
Jump to search
NCLEX nursing pharmacology monographs — batch import |
Add medication infobox (Drugbox) to monographs |
||
| Line 1: | Line 1: | ||
{{Drugbox | |||
| name = Ipratropium | |||
| brand = Atrovent | |||
| therapeutic = Bronchodilator | |||
| pharmacologic = Short-acting anticholinergic (SAMA) | |||
| onset = Onset 15 minutes; peak 1 to 2 hours; duration 4 to 6 hours. | |||
| halflife = Minimal systemic absorption; no routine level. | |||
| routes = Inhaled | |||
| highalert = No | |||
| blackbox = None | |||
| antidote = Supportive care. | |||
| pregnancy = Use if needed. | |||
}} | |||
<div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | <div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | ||
''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ||
Latest revision as of 16:09, 17 June 2026
| Drug monograph · NCLEX study reference | |
| Trade names | Atrovent |
|---|---|
| Therapeutic class | Bronchodilator |
| Pharmacologic class | Short-acting anticholinergic (SAMA) |
| Onset / peak / duration | Onset 15 minutes; peak 1 to 2 hours; duration 4 to 6 hours. |
| Half-life / level | Minimal systemic absorption; no routine level. |
| Routes | Inhaled |
| High-alert (ISMP) | No |
| Black box warning | None |
| Antidote / reversal | Supportive care. |
| Pregnancy / lactation | Use if needed. |
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Ipratropium (brand name Atrovent) — Bronchodilator; Short-acting anticholinergic (SAMA).
Identification
- Therapeutic class: Bronchodilator.
- Pharmacologic class: Short-acting anticholinergic (SAMA).
Pharmacology
- Mechanism of action: Blocks muscarinic receptors to reduce bronchoconstriction and secretions.
- Onset / peak / duration: Onset 15 minutes; peak 1 to 2 hours; duration 4 to 6 hours.
- Half-life / therapeutic level: Minimal systemic absorption; no routine level.
Clinical use
- Indications: COPD maintenance, acute bronchospasm (often with albuterol), rhinorrhea (nasal spray).
- Usual dose, route, frequency: Inhaler 2 puffs four times daily; nebulized 500 mcg.
- Maximum dose / adjustments: Per product.
Safety
- Contraindications: Hypersensitivity to atropine, soy or peanut (older MDI propellants).
- Black box warning: None.
- Interactions: Other anticholinergics (additive effects).
- Pregnancy / lactation: Use if needed.
- High-alert: No.
Adverse effects
- Common side effects: Dry mouth, cough, throat irritation.
- Serious effects to report: Acute angle-closure glaucoma if sprayed in the eyes, urinary retention.
- Antidote / reversal: Supportive care.
Nursing process
- Assessment before administration: Lung sounds, glaucoma and prostate history.
- Interventions during therapy: Avoid spraying near the eyes.
- Monitor: Respiratory status.
- Evaluation / expected outcome: Improved airflow.
Patient teaching
- Patient teaching: Rinse mouth for dryness; avoid eye contact.
- Notify provider if: Eye pain or vision changes, difficulty urinating.
- Administration tips: Maintenance, not primary rescue; keep out of eyes.